Completing data — refresh the page later to see the latest
106-52-5CN1CCC(O)CC1BAUWRHPMUVYFOD-UHFFFAOYSA-N106-52-5DTXSID9059339CHEMBL22332Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
This chemical does not meet GHS hazard criteria for 49.1% (52 of 106) of reports.
Danger
H315 (45.3%): Causes skin irritation [Warning Skin corrosion/irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P305+P354+P338, P317, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 106 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Status: Active Update: 30-06-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/19249
1-Methyl-4-piperidinol: Does not have an individual approval but may be used under an appropriate group standard
UsesReactant for:• ;Optimization of Novobiocin scaffold to product antitumor agents1• ;Substitution about the rigidifying ring for histamine H4 receptor antagonist synthesis2Reactant for synthesis of:• ;CaMKII inhibitors3• ;VEGFR and FGFR kinase inhibitors4• ;Phosphoinositide-3-kinase inhibitors5• ;Protein lysine methyltransferase G9a inhibitors6
Uses4-Hydroxy-1-methylpiperidine is used as reactant for optimization of Novobiocin scaffold to product antitumor agents, substitution about the rigidifying ring for histamine H4 receptor antagonist synthesis. It is also used as a reactant in the synthesis of CaMKII, VEGFR and FGFR kinase inhibitors and Phosphoinositide-3-kinase, Protein lysine methyltransferase G9a inhibitors.